ArticleFrontiers in immunology2026
Profiling immunogenic neoantigen peptides elicited by personalized neoantigen vaccine in cancer patients.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Personalized neoantigen vaccines can induce antitumor T cell responses, but only 10-20% of selected peptides have induced immune responses in patients, underscoring the limitations of current prediction strategies. Methods: We analyzed a clinically annotated dataset from 352 cancer patients who received personalized neoantigen peptide-pulsed dendritic cell vaccines. We focused on 2,317 short peptides derived from single nucleotide variants for which post-vaccination T cell responses were evaluated by IFN-γ ELISPOT assay. Immunogenic neoantigen peptides were defined as those inducing a ≥2.0-fold increase in IFN-γ ELISPOT responses after vaccination. We systematically examined peptide intrinsic characteristics and physicochemical properties, as well as predicted scores related to antigen-processing machinery. Results and discussion: Immunogenicity was not associated with specific mutation positions or sequence patterns but was significantly correlated with higher hydrophobicity (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.